Sympathetic Mechanisms in the Cardiovascular and Metabolic Alterations of Obesity, Crossover Design Study.

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY

We will study obese hypertensive subjects in a randomized, crossover study to determine if two weeks sympathetic blockade improves endogenous glucose production. Subjects will be studied on 3 different occasions after two weeks of receiving either placebo, amlodipine (vasodilator arm) or moxonidine (study arm). The order of the studies will be determined using computer-generated randomization. Patients will be blinded as to which treatment they are receiving on each day. An investigator blinded to the treatment assignment will perform the analysis of the data.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

• Males and females of all races between 18 and 65 years of age

• Hypertension defined by two or more properly measured seated blood pressure readings \>130/85 mmHg or currently on antihypertensive medication.

• Obesity will be defined as having a body mass index (BMI) ≥ 30 kg/m2.

• Able and willing to provide informed consent.

Locations
United States
Tennessee
Vanderbilt University Medical Center
RECRUITING
Nashville
Time Frame
Start Date: 2022-05-20
Estimated Completion Date: 2029-12-31
Participants
Target number of participants: 12
Treatments
Placebo_comparator: Placebo
Subjects will received 2 weeks of capsules containing placebo.
Active_comparator: Amlodipine
Subjects will received 2 weeks of capsules containing amlodipine.
Experimental: Moxonidine
Subjects will received 2 weeks of capsules containing moxonidine.
Related Therapeutic Areas
Sponsors
Leads: Vanderbilt University Medical Center

This content was sourced from clinicaltrials.gov